Dr. Dalton on the Future Treatment of Gynecologic Malignancies

Heather Dalton, MD
Published: Wednesday, May 31, 2017



Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses the future of treatment for gynecologic malignancies.

Dalton believes that platinum-based therapy and taxanes will remain the backbone of treatment for this disease. However, with the newest knowledge of BRCA and PARP inhibitors, she says, this landscape will hopefully have a stronger maintenance strategy.
 


Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses the future of treatment for gynecologic malignancies.

Dalton believes that platinum-based therapy and taxanes will remain the backbone of treatment for this disease. However, with the newest knowledge of BRCA and PARP inhibitors, she says, this landscape will hopefully have a stronger maintenance strategy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x